Active-controlled phase III study of an egg-cultivated quadrivalent inactivated split-virion influenza vaccine (GC3110A) in healthy Korean children aged 6–35 months

• Published in: Vaccine Vol. 39; no. 15; pp. 2103 - 2109
• Main Authors: Choi, Ui Yoon, Kim, Ki Hwan, Lee, Kyung Yil, Kim, Jong-Hyun, Kim, Chun Soo, Eun, Byung Wook, Kim, Hwang Min, Kim, Dong Ho, Song, Song Eun, Jo, Dae Sun, Lee, Jin, Ma, Sang Hyuk, Kim, Kwang Nam, Kang, Jin Han
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 08.04.2021; Elsevier Limited
• Subjects: Active control; Adverse events; Antibodies; Antigens; Children; Clinical trials; Confidence intervals; Deactivation; Discordance; Drug dosages; Evaluation; Guillain-Barre syndrome; Hemagglutination inhibition; Hospitals; Immunization; Immunogenicity; Influenza; Influenza B; Quadrivalent inactivated influenza vaccine; Safety; Seasons; Seroconversion; Surveillance; Vaccines; Virions; Hong Kong China; Singapore; United States > US; China; Children; Safety; Immunogenicity; Quadrivalent inactivated influenza vaccine
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2021.03.005

•We assessed the immunogenicity and safety of a quadrivalent influenza vaccine.•The study was conducted in children aged 6–35 months.•The vaccine fulfilled the Korean licensure criteria for immunogenicity.•The vaccine was safe and tolerable. The inactivated trivalent influenza vaccine (TIV) offers limited protection when two influenza B lineages co-circulate or when there is a vaccine mismatch (i.e., discordance in the predominant circulating B strain and WHO-recommended B strain). Inactivated quadrivalent influenza vaccine (QIV) may reduce the burden of influenza. Here, we report the results of a phase 3 clinical trial that evaluated the immunogenicity and safety of a novel QIV, GC3110A, in Korean children aged 6–35 months, which has been approved and is currently in use in Korea. The study involved two parts. In Part 1, the safety of GC3110A was evaluated in 10 subjects. After none of the subjects reported grade 3 adverse events (AEs), we proceeded to Part 2. Part 2 was a randomized, double-blind, multicenter phase 3 trial wherein we compared the immunogenicity and safety of GC3110A with those of a licensed control TIV. Immunogenicity was evaluated by measuring hemagglutination inhibition titers. The 200 participants enrolled in Part 2 were randomized in a 4:1 ratio to receive GC3110A or control TIV. The study vaccine group met both primary (i.e., the lower limit of 95% confidence interval [CI] of the seroconversion rate exceeds 40% for four strains) and secondary (i.e., the lower limit of 95% CI of the seroprotection rate exceeds 70% for four strains) immunogenicity endpoints. There was no significant between-group difference in the seroconversion rate, seroprotection rate, and geometric mean titer for the shared strains. However, the study vaccine group demonstrated significantly higher immunity for the additional strain B/Yamagata. In the safety analysis, there was no significant between-group difference in the proportion of participants with solicited local AEs, solicited systemic AEs, and unsolicited AEs. In conclusion, the results indicate that GC3110A has comparable immunogenicity and safety to those of TIV. Clinical Trial Registry Number: NCT03285997.